The newly approved oral formulation features a smaller pill size in 1.5mg, 4mg, and 9mg strengths while maintaining the efficacy and safety profile of the previous oral semaglutide version.

The research suggests that the increase is partly due to introduction of the HAART drug regimen, which transformed HIV from a terminal condition into a manageable chronic disease. HealthDay News — ...

HealthDay News — Dietary and lifestyle modifications are reasonable first-line therapies for symptomatic hemorrhoids, according to a clinical practice update issued by the American Gastroenterological ...

Gene therapy approved to restore hereditary hearing loss; investigational treatment shows hair coverage improvements in male ...

Patients received either mailed FIT with automated text message outreach from study personnel or mailed FIT-DNA with the ...

The Food and Drug Administration (FDA) has approved Auvelity ® (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer d ...

HealthDay News — The US Food and Drug Administration (FDA) is moving to speed drug development and review by launching ...

Data from ARTISTRY trials demonstrated that switching to a single-tablet regimen of bictegravir and lenacapavir is noninferior to continuing current antiretroviral therapy.

The Food and Drug Administration (FDA) has placed a hold on the enrollment of new patients in the phase 3 ENIGMA-TRS 2 study evaluating evenamide in treatment-resistant schizophre ...

However, most patients report preferring LAI-ART administered monthly or once every 2 months vs daily oral ART.

Similar incidence of death, new renal-replacement therapy, persistent kidney dysfunction reported with balanced fluid and 0.9 ...

Novo Nordisk submitted a BLA to the Food and Drug Administration for denecimig for the treatment of hemophilia A in September 2025.